Comparison of Mirabegron and Vibegron in Women With Treatment-Naive Overactive Bladder: A Randomized Controlled Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparison of Mirabegron and Vibegron in Women With Treatment-Naive Overactive Bladder: A Randomized Controlled Study

Published:2023-05 Issue: Volume:175 Page:67-73
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Kinjo Manami^ORCID,Masuda Kazuki,Nakamura Yu,Miyakawa Jimpei,Tambo Mitsuhiro,Fukuhara Hiroshi

Publisher

Elsevier BV

Subject

Urology

Reference30 articles.

1. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction;Haylen;Neurourol Urodyn,2010

2. An epidemiological survey of overactive bladder symptoms in Japan;Homma;BJU Int,2005

3. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study;Irwin;Eur Urol,2006

4. Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review;Bartoli;Urology,2010

5. The management of overactive bladder syndrome;Marinkovic;BMJ,2012

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Update on Therapies in Older Adults;Medical Clinics of North America;2024-09

2. Mirabegron 50 mg once daily, long-term treatment maximizes benefit in middle-aged and older people with overactive bladder syndrome: a systematic review and meta-analysis of nine phase II/III, randomized, double-blind, parallel-design, placebo-controlled, multicenter, and multinational trials;Frontiers in Surgery;2024-08-26

3. Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial;World Journal of Urology;2024-05-13

4. Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial;World Journal of Urology;2024-03-02

5. What is the best first choice oral drug therapy for OAB?;Neurourology and Urodynamics;2024-01-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3